Share
.webp)
.webp)
.webp)
.webp)
Eric Adler
Lexeo Therapeutics, Inc., has announced a series of strategic executive appointments to support the advancement of its pipeline into late-stage clinical development.
“The growing expertise within Lexeo’s leadership has been instrumental in driving some of the most impactful clinical programs, drug approvals, and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “We are excited to leverage the thought leadership and operational experience of our newly appointed executives as we transition our pipeline towards late-stage clinical studies.”
The new appointment include:
Eric Adler, MD has been appointed Chief Medical Officer & Head of Research. Dr. Adler, a recognized leader in cardiovascular gene therapy, has been with Lexeo since 2022, serving as Chief Scientific Officer. He previously held leadership positions at the University of California, San Diego, where his work led to the development of innovative cardiovascular gene therapies now entering late-stage trials. Dr. Adler is a prolific researcher with over 100 published papers and serves in leadership roles within the American Heart Association and other prestigious organizations.
